Neuberger Berman Group
CGTX icon

Neuberger Berman Group’s Cognition Therapeutics CGTX Stock Holding History

Neuberger Berman Group’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,884
Closed -$31.4K – 1824
2023
Q1 		$31.4K Buy
+15,884
New +$30.3K ﹤0.01% 1774

Other funds holding CGTX

PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
PWM
Perigon Wealth Management San Francisco, California $5.51B AUM 24.51% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Neuberger Berman Group's CGTX Position: Q2 2023 in Review

Neuberger Berman Group sold out of Cognition Therapeutics (CGTX) in Q2 2023, closing a stake of 15,884 shares — an estimated $31.4K sold.

Neuberger Berman Group first reported a position in CGTX in Q1 2023 and held it in 1 quarter. The position peaked at $31.4K in Q1 2023. 35 funds tracked by Wall St. Rank hold CGTX as of Q2 2023.

  • Neuberger Berman Group reported no remaining Cognition Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Neuberger Berman Group sold 15,884 Cognition Therapeutics shares in Q2 2023, an estimated $31.4K.
  • Neuberger Berman Group first reported a position in Cognition Therapeutics in Q1 2023 and held it in 1 quarter.
  • Neuberger Berman Group's Cognition Therapeutics position peaked at $31.4K in Q1 2023.
  • 35 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2023.

Based on Neuberger Berman Group's 13F filing for Q2 2023, filed 11 Aug 2023.